MedTrace Logo

Nasal Oxcytocin During IUI

NCT00805662 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2008-12-09

No results posted yet for this study

Summary

Placebo-controlled study. Application of nasal oxytocin (8 IU) during intrauterine insemination in 86 patients.

Conditions

  • Idiopathic Infertility

Interventions

DRUG

oxytocin, placebo

intranasal oxytocin during intrauterine insemination

Sponsors & Collaborators

  • Organon GmbH (former name)

    collaborator UNKNOWN

  • Essex Pharma GmbH

    collaborator INDUSTRY

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
43 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00805662 on ClinicalTrials.gov